Madam Speaker, I thank my colleague for his speech.
He spoke a lot about rare diseases and the high cost of drugs. I have a few numbers to illustrate what he was saying. Between 2007 and 2017, the average annual cost of treatment for the top 10 selling patented medicines in Canada increased by 800%. The number of medicines with annual per-patient treatment costs of at least $10,000 increased sevenfold, going from 20 to 135.
Does my colleague agree that we need to support the regulations excluding the United States and Switzerland, which would enable us to save $9 billion over 10 years? That could impact the most expensive drugs.